Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck
Bristol Myers Squibb and Merck are locked in a heated race to bring their blockbuster PD-(L)1 drugs into early cancer patients as part of potentially …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
